On November 17, 2025, Solve Therapeutics, a clinical-stage biotechnology company developing best-in-class antibody-drug conjugates (ADCs) for solid tumor malignancies, announced it raised $120 million in an oversubscribed and upsized financing to accelerate the development of its clinical pipeline and proprietary CloakLink™ linker platform. This latest funding follows a $75 million financing completed in December 2024, bringing Solve’s total capital raised to $321 million. Wilson Sonsini Goodrich & Rosati advised Solve Therapeutics on patent matters related to the transaction.

The new funding will support the completion of Phase 1b studies for Solve’s lead programs (SLV-154 and SLV-324) that are currently in Phase 1 clinical trials in patients with solid tumors and expand the company’s operational capabilities as it advances toward later-stage clinical development.

The Wilson Sonsini team that advised Solve on the transaction was led by Uale Taotafa, Mike Hostetler, Jose Martinez, Jane Yang, and Heng Zhang.

For more information, please see Solve Therapeutics’ news release.